Ahmed Bendari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ahmed Bendari has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Alaa Bendari
Department of Medical Biochemistry, Faculty of medicine, Zagazig University, Zagazig 44519, Al-Sharqia Governorate, Egypt
1 shared publication - Brett Baskovich
Department of Pathology and Laboratory Medicine, Molecular Genetic Pathology Division, Mount Sinai Hospital, New York, NY 10029, USA
1 shared publication - Juan Luis Gomez Marti
Department of Pathology University of Pittsburgh School of Medicine Pittsburgh Pennsylvania USA
1 shared publication - Kritika Krishnamurthy
Department of Pathology and Laboratory Medicine, Montefiore Medical Center, Bronx, NY 10467, USA
1 shared publication - Mona Sebika
Department of pathology, Faculty of medicine, Menoufia University, Shebin El-Kom 32511, Menoufia Governorate, Egypt
1 shared publication - Oana Vele
Department of Pathology and Laboratory Medicine, Lenox Hill Hospital, New York, NY 10075, USA
1 shared publication
Latest Publications
- Open Access
- 19 October 2025
- Published by MDPI AG in Gastroenterology Insights
- Vol. 16 (4) , 39
Liquid Biopsy in Pancreatic Ductal Adenocarcinoma: Clinical Utility, Trials, and Future Directions
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy marked by late diagnosis, rapid progression, and poor prognosis, with a 5-year survival rate of 2–9%. Traditional tissue biopsy faces limitations in accessibility and real-time monitoring. Liquid biopsy—a minimally invasive technique analyzing tumor-derived materials such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, tumor-educated platelets (TEPs), and cell-free RNAs (cfRNAs)—offers dynamic insights into PDAC biology. This review advances beyond the prior literature by offering a unified synthesis that bridges molecular mechanisms, biomarker dynamics, and clinical translation within the context of PDAC. It also summarizes key clinical trials evaluating liquid biopsy in PDAC, underscoring its growing impact on precision oncology.
- 19 October 2025
- Published by MDPI AG in Gastroenterology Insights
- Vol. 16 (4) , 39
Open AccessLiquid Biopsy in Pancreatic Ductal Adenocarcinoma: Clinical Utility, Trials, and Future Directions
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy marked by late diagnosis, rapid progression, and poor prognosis, with a 5-year survival rate of 2–9%. Traditional tissue biopsy faces limitations in accessibility and real-time monitoring. Liquid biopsy—a minimally invasive technique analyzing tumor-derived materials such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, tumor-educated platelets (TEPs), and cell-free RNAs (cfRNAs)—offers dynamic insights into PDAC biology. This review advances beyond the prior literature by offering a unified synthesis that bridges molecular mechanisms, biomarker dynamics, and clinical translation within the context of PDAC. It also summarizes key clinical trials evaluating liquid biopsy in PDAC, underscoring its growing impact on precision oncology.